β-Lapachone
产品说明书
 |
同义名 : | beta-拉帕醌 ;ARQ-501; NSC-26326; SL 11001; NSC 629749; Beta-Lapachone |
| CAS号 : | 4707-32-8 | |
| 货号 : | A951815 | |
| 分子式 : | C15H14O3 | |
| 纯度 : | 99%+ | |
| 分子量 : | 242.27 | |
| MDL号 : | MFCD01712233 | |
| 存储条件： |
Pure form Sealed in dry,2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 靶点 |
|
||
| 描述 | β-Lapachone functions as a topoisomerase I inhibitor. At a concentration of 25 μM, β-Lapachone inhibits camptothecin-induced DNA cleavage [1]. Lapachone (at concentrations ranging from 10 to 40 μM) significantly diminishes the colony-forming ability of CHO cells and demonstrates cytotoxicity during the S phase. Additionally, β-Lapachone induces substantial DNA strand breaks in CHO cells at concentrations exceeding 10 μM [2]. β-Lapachone (10 μM) inhibits JCPyV replication in IMR-32 cells. β-Lapachone at 1.0 μM significantly impacts JCPyV propagation in JCI cells. Moreover, β-Lapachone at concentrations ranging from 0.01 to 0.1 μM inhibits VP1 production in JCI cells [4]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT03575078 | Lymphoma | Phase 1 | Not yet recruiting | August 23, 2023 | - |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
4.13mL 0.83mL 0.41mL |
20.64mL 4.13mL 2.06mL |
41.28mL 8.26mL 4.13mL |
